STAT+: Biotech companies are struggling to navigate Trump’s new tariffs
AI Summary
Smaller biotech companies are working to understand how to obtain exemptions from new tariffs imposed by the Trump administration. The import taxes are creating uncertainty for firms that rely on cross-border goods and supply chains.
Smaller biotech firms are trying to figure out how to win exemptions from Trump's import taxes.
Politics Markets Health Commodities biotech tariffs Trump administration trade policy import exemptions pharmaceutical supply chains